keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/29225833/longer-recurrence-free-survival-in-a-patient-with-metastatic-renal-cell-carcinoma-treated-with-temsirolimus
#1
Tendo Satoh, Takuya Koie, Hirotaka Horiguchi, Noriko Tokui, Satoshi Narita, Chikara Ohyama
Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second-line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression-free survival rate remains short. We report one patient with mRCC who had a continuing response to temsirolimus.
December 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/29201463/complex-monitoring-of-biochemical-and-radionuclide-parameters-in-patients-with-metastatic-renal-cell-carcinoma-during-immunotherapy
#2
M S Sayapina, S G Averinova, T V Zacharova, A V Kashkadaeva, S V Shiryaev, M V Poluectova, O A Vorob'eva
Study Objective: To study the effectiveness of complex monitoring of the kidney function, based on biochemical and radionuclide methods in patients with metastatic renal cell carcinoma (mRCC). Materials and Methods: 41 mRCC patients after nephrectomy received nivolumab (n = 23) and interferon-α (n = 18) from 2015 to 2017. At baseline and 2 months after, all patients underwent blood chemistry, urinalysis, Rehberg test, and ELISA to determine serum levels of IL-17A, TGF-β, and erythropoietin...
2017: International Journal of Nephrology
https://www.readbyqxmd.com/read/29198329/examining-the-bleeding-incidences-associated-with-targeted-therapies-used-in-metastatic-renal-cell-carcinoma
#3
REVIEW
MacKenzie Crist, Elizabeth Hansen, Lipika Chablani, Elizabeth Guancial
A systematic review was conducted to illustrate the bleeding risks associated with targeted therapies used in the treatment of metastatic renal cell carcinoma (mRCC). Eligible studies included phase II, III, or IV clinical trials using pazopanib, sunitinib, cabozantinib, lenvatinib, everolimus, temsirolimus, bevacizumab, axitinib, and/or sorafenib in the setting of mRCC. Types of bleeding event(s), bleeding event frequency, and incidence of thrombocytopenia were collected from the relevant articles. ClinicalTrials...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29195016/association-of-high-cost-sharing-and-targeted-therapy-initiation-among-elderly-medicare-patients-with-metastatic-renal-cell-carcinoma
#4
Pengxiang Li, Yu-Ning Wong, Jordan Jahnke, Amy R Pettit, Jalpa A Doshi
High out-of-pocket costs may limit access to oral therapies covered by patients' prescription drug benefits. We explored financial barriers to treatment initiation in patients newly diagnosed with metastatic renal cell carcinoma (mRCC) by comparing Medicare Part D patients with low out-of-pocket costs due to receipt of full low-income subsidies (LIS beneficiaries) to their counterparts who were responsible for more than 25% cost sharing during Medicare's initial coverage phase (non-LIS beneficiaries). We used 2011-2013 100% Medicare claims for non-LIS and LIS beneficiaries newly diagnosed with metastases in the liver, lung, or bone to examine targeted therapy treatment initiation rates and time to initiation for (1) oral medications (sorafenib, sunitinib, everolimus, pazopanib, or axitinib) covered under Medicare's prescription drug benefit (Part D); (2) injected or infused medications (temsirolimus or bevacizumab) covered by Medicare's medical benefit (Part B); and (3) any (Part D or Part B) targeted therapy...
December 1, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29192741/taribo-trial-targeted-therapy-with-or-without-nephrectomy-in-metastatic-renal-cell-carcinoma-liquid-biopsy-for-biomarkers-discovery
#5
Elena Verzoni, Raffaele Ratta, Paolo Grassi, Roberto Salvioni, Silvia Stagni, Rosanna Montone, Giovanni Fucà, Vera Cappelletti, Carolina Reduzzi, Ugo De Giorgi, Giuseppe Procopio
PURPOSE: Two randomized trials in the cytokine era showed that cytoreductive nephrectomy (CN) had a role in metastatic renal cell carcinoma (mRCC), increasing life expectancy. The survival benefit of tyrosine kinase inhibitors (TKIs), including first-line sunitinib and pazopanib, in mRCC has been demonstrated, but the majority of patients enrolled in the pivotal phase III studies had undergone nephrectomy. Therefore it is unknown if similar survival benefit with targeted agents could be achieved without CN...
November 29, 2017: Tumori
https://www.readbyqxmd.com/read/29187872/tumoral-anxa1-is-a-predictive-marker-for-sunitinib-treatment-of-renal-cancer-patients
#6
Marjut Niinivirta, Gunilla Enblad, Per-Henrik Edqvist, Fredrik Pontén, Anca Dragomir, Gustav J Ullenhag
Background and aims: There is no established predictive marker for the treatment of renal cancer. Metastatic renal cell carcinoma (mRCC) patients are often treated with sunitinib, a tyrosine kinase inhibitor. Sunitinibs anti-cancer effect is at least partly mediated through interfering with angiogenesis. Our aim with the current study was to assess annexin A1 (ANXA1), which stimulates angiogenesis, as a predictive marker for sunitinib therapy in mRCC patients. Since previous studies have indicated a predictive potential for cubilin, we also investigated the predictivity of ANXA1 combined with cubilin...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29174942/comparative-effectiveness-of-initial-surgery-versus-initial-systemic-therapy-for-metastatic-kidney-cancer-in-the-targeted-therapy-era-analysis-of-a-population-based-cohort
#7
Liam C Macleod, Anobel Y Odisho, Scott S Tykodi, Sarah K Holt, Jonathan D Harper, John L Gore
OBJECTIVE: To use econometric methods to assess comparative overall survival of mRCC patients managed with initial cytoreductive nephrectomy (CN) versus initial systemic therapy. Randomized data demonstrate improved survival for CN preceding cytokine-based therapy in metastatic renal cell carcinoma (mRCC). This benefit may be attenuated in the contemporary mRCC era given more effective systemic therapies. METHODS: Patients over age 65 with mRCC from the Surveillance, Epidemiology, and End Results (SEER) registries linked with Medicare claims from 2006-2011 were categorized by initial treatment...
November 23, 2017: Urology
https://www.readbyqxmd.com/read/29173270/clinical-outcomes-of-the-sequential-use-of-pazopanib-followed-by-everolimus-for-the-treatment-of-metastatic-renal-cell-carcinoma-a-multicenter-study-in-korea
#8
Jeong Ho Kim, Wan Lee, Tae Nam Kim, Jong Kil Nam, Tae Hyo Kim, Ki Soo Lee
INTRODUCTION: The aim of this study was to investigate the real-world clinical outcomes of first-line pazopanib and second-line everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). METHODS: Data of patients who had mRCC with clear-cell component between 2001 and 2015 at multiple institutions were collected retrospectively. To be included in the analysis, patients had to meet the following criteria: age≥18 years; received first-line targeted therapy with pazopanib; and received second-line targeted therapy with everolimus...
December 1, 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29172746/pazopanib-for-renal-cell-carcinoma-leads-to-elevated-mean-arterial-pressures-in-a-murine-model
#9
Amber Kempton, Cody Justice, Aaron Guo, Matthew Cefalu, Michael Makara, Paul Janssen, Thai H Ho, Sakima A Smith
BACKGROUND: In the setting of metastatic RCC (mRCC), pazopanib is approved as first line therapy. Unfortunately treatment may lead to cardiotoxicity such as hypertension, heart failure, and myocardial ischemia. OBJECTIVE: Define the in vivo role of pazopanib in the development of cardiotoxicity. METHODS: Wild type mice were dosed for 42 days via oral gavage, and separated into control and treatment (pazopanib) groups. Baseline ECG's, echocardiograms, and blood pressures were recorded...
November 27, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/29146617/cure-in-advanced-renal-cell-cancer-is-it-an-achievable-goal
#10
Dhanusha Sabanathan, John J Park, Manuel Marquez, Louise Francisco, Natalie Byrne, Howard Gurney
BACKGROUND: Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%-30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29144161/use-of-patient-outcome-endpoints-to-identify-the-best-functional-ct-imaging-parameters-in-metastatic-renal-cell-carcinoma-patients
#11
Jill Rachel Mains, Frede Donskov, Erik Morre Petersen, Hans Henrik Torp Madsen, Jesper Thygesen, Kennet Thorup, Finn Rasmussen
OBJECTIVE: To use the patient outcome endpoints overall survival and progression-free survival to evaluate functional parameters derived from dynamic contrast-enhanced computed tomography (DCE-CT). METHODS: 69 patients with metastatic renal cell carcinoma (mRCC) had DCE-CT scans at baseline and after 5 and 10 weeks of treatment. Blood volume, blood flow and standardized perfusion values were calculated using deconvolution (BVdeconv, BFdeconv and SPVdeconv), blood flow and standardized perfusion values using maximum slope (BFmax and SPVmax), and blood volume and permeability surface area product using the Patlak model (BVpatlak and PS)...
November 16, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/29128421/trends-in-usage-of-cytoreductive-partial-nephrectomy-and-effect-on-overall-survival-in-patients-with-metastatic-renal-cell-carcinoma
#12
Andrew T Lenis, Amirali H Salmasi, Nicholas M Donin, Izak Faiena, David C Johnson, Alexandra Drakaki, Kiran Gollapudi, Jeremy Blumberg, Arie S Belldegrun, Allan J Pantuck, Karim Chamie
PURPOSE: Cytoreductive radical nephrectomy (cRN) improves survival in select patients with metastatic renal cell carcinoma (mRCC). It is unclear, however, whether cytoreductive partial nephrectomy (cPN) compromises oncologic efficacy. We evaluated trends in utilization of cPN and compared overall survival (OS) in patients who underwent cRN or cPN for mRCC. MATERIALS AND METHODS: We queried the National Cancer Database from 2006 to 2013 and identified patients who underwent cPN and cRN for mRCC...
November 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29120911/immunotherapy-for-kidney-cancer-status-quo-and-the-future
#13
Jens Bedke, Viktoria Stühler, Arnulf Stenzl, Bernhard Brehmer
PURPOSE OF REVIEW: The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI). The review focus on the recent immunooncology developments and available trial results within the last 12 months. RECENT FINDINGS: ICI as monotherapy (nivolumab) or immunooncology and immunooncology combinations (nivolumab and ipilimumab) demonstrated positive results on prolonged overall survival in phase III trials...
November 7, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29119013/lung-metastasectomy-following-kidney-tumors-outcomes-and-prognostic-factors-from-a-single-center-experience
#14
Elisa Meacci, Dania Nachira, Maria Teresa Congedo, Venanzio Porziella, Marco Chiappetta, Gianmaria Ferretti, Amedeo Iaffaldano, Leonardo Petracca Ciavarella, Stefano Margaritora
Background: The lung is one of the sites most frequently affected by metastatic renal cell carcinoma (mRCC). Nonsurgical therapy for mRCC has limited efficacy, while the 5-year survival rates data published in literature after pulmonary surgery for metastasectomy, emphasize the role of surgery as the treatment that guarantees the best effectiveness in pulmonary resectable metastases. Methods: From January 2000 to March 2016, 27 patients underwent pulmonary metastasectomy for metastatic renal cancer was retrospectively reviewed...
October 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29118527/unusual-pattern-of-whitening-of-eyebrows-following-sunitinib-therapy-a-case-report-with-brief-review-of-literature
#15
Chaturbhuj R Agrawal, Vineet Talwar, Venkata Pradeep Babu, Parveen Jain, Pankaj Goyal
Sunitinib is a vascular endothelial growth factor receptor inhibitor which has shown high activity in metastatic renal cell carcinoma (mRCC) patients and is now widely used for the same. It is generally well tolerated, but sometimes, it exhibits a distinct pattern of novel side effects that require monitoring and management. Important known side effect of sunitinib includes fatigue, diarrhea, anorexia, skin toxicity, and hypertension which need special mention. Considering its effectiveness in first-line setting in mRCC and paucity of other good options, utmost efforts are made to continue it with identification of side effects which may require only slight dose modification or no dose alteration...
October 2017: International Journal of Trichology
https://www.readbyqxmd.com/read/29108268/inherent-characteristics-of-metachronous-metastatic-renal-cell-carcinoma-in-the-era-of-targeted-agents
#16
Jang Hee Han, Seung Hwan Lee, Won Sik Ham, Woong Kyu Han, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Young Eun Yoon
Background: To assess the prognostic and predictive factors of time to treatment failure (TTF) and overall survival (OS), respectively, in patients with metachronous metastatic renal cell carcinoma (mRCC) who were treated with targeted agents. Materials and Methods: We retrospectively reviewed metachronous mRCC patients, defined as individuals diagnosed with metastatic disease >3 months after initial nephrectomy, treated at an institute since 2005. Cox proportional hazard regression analysis was performed to discover the most determinant variables associated with TTF and OS...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29103965/overall-survival-in-patients-with-metastatic-renal-cell-carcinoma-and-clinical-n1-disease-undergoing-cytoreductive-nephrectomy-and-lymph-node-dissection
#17
Izak Faiena, Amirali Salmasi, Andrew T Lenis, Nicholas M Donin, David C Johnson, Kinan Bachour, Alexandra Drakaki, Arie S Belldegrun, Allan J Pantuck, Karim Chamie
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) have limited treatment options. Cytoreductive nephrectomy (CN) in select patients has been associated with improved survival. We aim to assess the survival in patients with mRCC and cN1 disease who underwent CN with and without lymph node dissection (LND). METHODS: Data were abstracted from the National Cancer Database for patients diagnosed with mRCC and cN1 from 2003 to 2014. Using propensity matching, we compared overall survival (OS) in patients who underwent a LND...
November 2, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29099775/whole-blood-mrna-expression-based-prognosis-of-metastatic-renal-cell-carcinoma
#18
Karthik V Giridhar, Carlos P Sosa, David W Hillman, Cristobal Sanhueza, Candace L Dalpiaz, Brian A Costello, Fernando J Quevedo, Henry C Pitot, Roxana S Dronca, Donna Ertz, John C Cheville, Krishna Vanaja Donkena, Manish Kohli
The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score is based on clinical parameters. We analyzed whole blood mRNA expression in metastatic clear cell renal cell carcinoma (mCCRCC) patients and compared it to the MSKCC score for predicting overall survival. In a discovery set of 19 patients with mRCC, we performed whole transcriptome RNA sequencing and selected eighteen candidate genes for further evaluation based on associations with overall survival and statistical significance. In an independent validation of set of 47 patients with mCCRCC, transcript expression of the 18 candidate genes were quantified using a customized NanoString probeset...
November 3, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29066973/from-resistance-to-sensitivity-insights-and-implications-of-biphasic-modulation-of-autophagy-by-sunitinib
#19
REVIEW
Amal Kamal Abdel-Aziz, Ashraf B Abdel-Naim, Samia Shouman, Saverio Minucci, Mohamed Elgendy
Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in metastatic renal cell carcinoma (mRCC) and is also used in treating patients with pancreatic neuroendocrine and imatinib-resistant gastrointestinal stromal tumors (GIST). Nevertheless, most patients eventually relapse secondary to intrinsic or acquired sunitinib resistance. Autophagy has been reported to contribute to both chemo-sensitivity and -resistance. However, over the last few years, controversial regulatory effects of sunitinib on autophagy have been reported...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29062235/real-world-experience-of-everolimus-as-second-line-treatment-in-metastatic-renal-cell-cancer-after-failure-of-pazopanib
#20
Konstantinos Koutsoukos, Aristotelis Bamias, Kimon Tzannis, Marta Espinosa Montaño, Vasiliki Bozionelou, Christos Christodoulou, Dimitra Stefanou, Haralabos Kalofonos, Ignacio Duran, Konstantinos Papazisis
AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed...
2017: OncoTargets and Therapy
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"